Two Botox Studies Published (and it’s good news for Botox)
On March 17th 2010, the journal Cephalalgia published two studies on Botox from the PREEMPT 1 and 2 trials. These are both phase 3 studies, and it’s still looking good for Botox.
Both of the trials were for chronic migraine sufferers. The patients were given Botox injections every 12 weeks.
The PREEMPT 1 trial found a significant decrease in days with headache and migraine, hours of headache and moderate to severe headache days. Though actual number of attacks were not significantly lessened, the attacks were lessened quite a bit.
The PREEMPT 2 trial also found a significant decrease in headache days within a 28 day period.
More good news – very few patients had problems with the injections (ie side effects) that were significant enough that they stopped the trial.
One proponent for Botox use in migraine treatment is Dr. Alexander Mauskop of the New York Headache Center. He writes that he’s hoping to see FDA approval (in the USA, of course) for Botox before the end of the year.
Stay tuned.